UF Health Oakleaf — Orange Park, Florida

UF Health Oakleaf is a clinical research site located in Orange Park, Florida, United States 32065.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

UF Health Oakleaf has participated in 1 clinical trials.

Therapeutic areas: Cardiovascular Diseases, Cancer, Liver Diseases.

Sponsors: Duke University.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Orange Park

Browse all research sites in Florida · View every site in Orange Park

• Park Avenue Dermatology
• Florida Radiation Oncology Group
• Integrated Community Oncology Network - Orange Park
• 21st Century Oncology-Orange Park
• Park Avenue Dermatology PA
• Florida Oncology Associates
• Research Site
• Orange Park Medical Center
• North Florida Gastroenterology Research, LLC
• Arthritis & osteoporosis treatment center,PA
• Integrated Community Oncology Network
• Flora Chen Poveda, OD, PA

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for UF Health Oakleaf?

UF Health Oakleaf has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has UF Health Oakleaf conducted?

UF Health Oakleaf has 1 clinical trials on record. Their work covers Cardiovascular Diseases, Cancer, Liver Diseases.

Is UF Health Oakleaf accredited by Crixeo Clinical Trials?

UF Health Oakleaf has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about UF Health Oakleaf?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.